Clincosm LogoSign in Get a demo

Taste Properties of HIV Inhibitor

Sponsor
ViiV Healthcare (Industry)
Overall Status
Completed
CT.gov ID
NCT02608918
Collaborator
Senopsys, LLC (Industry)
8
Enrollment
1
Location
1
Arm
4.6
Actual Duration (Months)
1.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to assess the taste properties of HIV inhibitor

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
8 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
An Open-Label Taste Assessment of BMS-955176 in Healthy Subjects
Actual Study Start Date :
Jan 5, 2016
Actual Primary Completion Date :
May 24, 2016
Actual Study Completion Date :
May 24, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: BMS-955176

BMS-955176 specified dose on specified days

Drug: BMS-955176
Other Names:
  • HIV Maturation Inhibitor

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Taste properties of HIV Inhibitor will be measured using the Flavor Profile of the Flavor Leadership Criteria [Up to 2 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

    Inclusion Criteria:

    • Men and women of non-childbearing potential professional sensory panelists

    • Aged between 25 and 80 years

    Exclusion Criteria:

    • History of relevant drug or food allergies, cardiovascular or Central nervous system (CNS) disease, clinically significant pathology, history of mental illness

    • Positive HIV test

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 GSK Investigational Site Woburn Massachusetts United States 01801

    Sponsors and Collaborators

    • ViiV Healthcare
    • Senopsys, LLC

    Investigators

    • Study Director: Viiv Clinical Trials, ViiV Healthcare

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    ViiV Healthcare
    ClinicalTrials.gov Identifier:
    NCT02608918
    Other Study ID Numbers:
    • 206301
    • AI468-065
    First Posted:
    Nov 20, 2015
    Last Update Posted:
    Apr 17, 2018
    Last Verified:
    Apr 1, 2018
    Additional relevant MeSH terms:
    HIV Infections
    BMS-955176

    Study Results

    No Results Posted as of Apr 17, 2018